CANCER:

Waldenstrom Macroglobulinemia

Related cancers:

‹

›

CXCR4 mutation CXCR4 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	ibrutinib + BMS-936564 Sensitive: C3 – Early Trials Blood - 1 week
MYD88 L265P MYD88 L265P	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	zanubrutinib Sensitive: C3 – Early Trials Clin Cancer Res - 3 weeks
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	zanubrutinib Sensitive: A1 - Approval
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab + ibrutinib Sensitive: A1 - Approval
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	ibrutinib Sensitive: A1 - Approval
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	acalabrutinib Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	fludarabine oral Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	cladribine Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab + bortezomib Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	everolimus Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	bortezomib Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	ofatumumab Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab + carfilzomib + dexamethasone Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	R-CHOP Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	IRd Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	FCR Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	bortezomib + dexamethasone Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	bendamustine Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	BDR Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	BR Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	CaRD Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	RCD Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	RCP Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	I-131-CLR1404 Sensitive: B - Late Trials
MYD88 mutation MYD88 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	ibrutinib Sensitive: C2 – Inclusion Criteria
CXCR4 mutation CXCR4 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	ibrutinib Sensitive: C2 – Inclusion Criteria
CXCR4 mutation CXCR4 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C2 – Inclusion Criteria
MYD88 L265P MYD88 L265P	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C2 – Inclusion Criteria
CXCR4 mutation CXCR4 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	venetoclax Sensitive: C2 – Inclusion Criteria
MYD88 mutation + CXCR4 mutation MYD88 mutation + CXCR4 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	ibrutinib Sensitive: C2 – Inclusion Criteria
CXCR4 mutation CXCR4 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	BDR Sensitive: C3 – Early Trials
CXCR4 mutation CXCR4 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab + carfilzomib Sensitive: C3 – Early Trials
CXCR4 G336X CXCR4 G336X	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials
CXCR4 S338X CXCR4 S338X	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials
CXCR4 H350fs* CXCR4 H350fs*	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials
CXCR4 S338X + TP53 R196X CXCR4 S338X + TP53 R196X	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials
CXCR4 K327fs* CXCR4 K327fs*	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials
CXCR4 R338X CXCR4 R338X	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials
CXCR4 T318fs* CXCR4 T318fs*	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials
CXCR4 L326fs* CXCR4 L326fs*	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials
CXCR4 S347fs* CXCR4 S347fs*	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials
MYD88 L265P + CXCR4 mutation MYD88 L265P + CXCR4 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	venetoclax Resistant: C3 – Early Trials
MYD88 L265P MYD88 L265P	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	venetoclax Sensitive: C3 – Early Trials
CD38 expression CD38 expression	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	daratumumab Sensitive: C3 – Early Trials
MYD88 L265P MYD88 L265P	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	daratumumab Sensitive: C3 – Early Trials
CXCR4 mutation CXCR4 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	daratumumab Sensitive: C3 – Early Trials
CXCR4 mutation CXCR4 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	ibrutinib + X4P-001 Sensitive: C3 – Early Trials
MYD88 L265P MYD88 L265P	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	X4P-001 Sensitive: C3 – Early Trials
MYD88 mutation MYD88 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab Sensitive: C4 – Case Studies

Waldenstrom Macroglobulinemia

Associations(51)

Associations
(51)